Conjugated To A Detectable Label Or Radioisotope Or Radionuclide Or Heavy Metal-containing Compound Patents (Class 530/391.3)
-
Publication number: 20140199242Abstract: Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the MUC4 protein that does not comprise the central tandem repeat (TR) domain of MUC4. Certain antibodies bind to the MUC4 peptide fragment MUC4-?-N-Ter and/or to the MUC4 peptide fragment MUC4-?-C-Ter. Chimeric constructs comprising such antibodies are also provided.Type: ApplicationFiled: June 6, 2012Publication date: July 17, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Surinder K. Batra, Maneesh Jain, Moorthy P. Ponnusamy
-
Patent number: 8779104Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: GrantFiled: August 21, 2013Date of Patent: July 15, 2014Assignee: The Regents of the University of CaliforniaInventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
-
Patent number: 8778699Abstract: A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.Type: GrantFiled: August 4, 2011Date of Patent: July 15, 2014Assignee: Idexx Laboratories, Inc.Inventors: Mahalakshmi Yerramilli, Michael Atkinson, Murthy V. S. N. Yerramilli
-
Patent number: 8778885Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: GrantFiled: June 8, 2011Date of Patent: July 15, 2014Assignee: Amorfix Life Sciences Ltd.Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Publication number: 20140193830Abstract: Provided are biosensors, compositions comprising biosensors, and methods of using biosensors in living cells and organisms. The biosensors are able to be selectively targeted to certain regions or structures within a cell. The biosensors may provide a signal when the biosensor is targeted and/or in response to a property of the cell or organism such as membrane potential, ion concentration or enzyme activity.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Inventors: Brigitte F. Schmidt, Christopher S. Szent-Gyorgyi, Alan S. Waggoner, Peter B. Berget, Marcel P. Bruchez, Jonathan W. Jarvik
-
Publication number: 20140193849Abstract: There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: Agency for Science, Technology and ResearchInventors: Karthikeyan Narayanan, Andrew Chwee Aun Wan, Jackie Y. Ying, Nandanan Erathodiyil
-
Publication number: 20140193417Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: ApplicationFiled: September 26, 2013Publication date: July 10, 2014Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Publication number: 20140193419Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: July 10, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140193405Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicants: Seattle Genetics, Inc., Genentech, Inc.Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
-
Publication number: 20140193429Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.Type: ApplicationFiled: March 17, 2014Publication date: July 10, 2014Applicant: SYRACUSE UNIVERSITYInventors: Robert P. Doyle, Joshua J. Lensbouer
-
Patent number: 8772459Abstract: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.Type: GrantFiled: December 2, 2010Date of Patent: July 8, 2014Assignee: ImaginAb, Inc.Inventors: David Ho, Tove Olafsen, Arye Lipman
-
Patent number: 8772501Abstract: The present invention provides fluorescent dyes that are based on firefly luciferin structure. These dyes are optimally excited at shorter wavelengths and have Stokes shift of at least 50 nm. The fluorescent dyes of the invention are useful for preparation of dye-conjugates, which can be used in detection of an analyte in a sample.Type: GrantFiled: January 24, 2013Date of Patent: July 8, 2014Assignee: Beckman Coulter, Inc.Inventors: Hashem Akhavan-Tafti, Renuka De Silva, Guoping Wang, Robert A. Eickholt, Ravinder Gupta, Lakshmi S. Kaanumalle
-
Publication number: 20140186917Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.Type: ApplicationFiled: July 25, 2013Publication date: July 3, 2014Applicant: Deutsches KrebsforschungszentrumInventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
-
Publication number: 20140186383Abstract: Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which include isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.Type: ApplicationFiled: August 29, 2013Publication date: July 3, 2014Applicants: Johns Hopkins University, The Government of the U.S.A as Represented by the Secretary of the Department of HeInventors: William M. Switzer, Walid Heneine, Thomas M. Folks, Nathan D. Wolfe, Donald S. Burke, David M. Sintasath
-
Publication number: 20140186377Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Type: ApplicationFiled: November 26, 2013Publication date: July 3, 2014Applicant: AbbVie, Inc.Inventors: Jijie Gu, Charles W. Hutchins, Rong-Rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Tariq Ghayur, Paul R. Hinton, Veronica M. Juan, John Mankovich, Junjian Liu
-
Publication number: 20140186831Abstract: Solid supports for chemiluminescent assays are provided. The solid support includes a plurality of probes covalently or physically attached to the support surface and a chemiluminescent enhancing moiety incorporated onto the surface or into the bulk of the support. The solid support can be a multi-layered support including an upper probe binding layer (e.g., an azlactone polymer layer or porous functional polyamide layer) adjacent to a cationic microgel layer. The azlactone-functional polymer can be a copolymer of dimethylacrylamide and vinylazlactone crosslinked with ethylenediamine. The cationic microgel layer can be a cross-linked quaternary onium salt containing polymer. A method and a kit for conducting chemiluminescent assays using the solid supports is also provided. The kit comprises a dioxetane substrate, a biopolymer probe-enzyme complex, and a solid support.Type: ApplicationFiled: November 1, 2013Publication date: July 3, 2014
-
Patent number: 8765920Abstract: A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an Ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small molecule, peptide, and protein modification. The tyrosine ligation reactions are shown to be compatible with the labeling of native enzymes and antibodies in buffered aqueous solution. This reaction provides a novel synthetic approach to bispecific antibodies. This reaction will find broad utility in peptide and protein chemistry and in the chemistry of phenol-containing compounds.Type: GrantFiled: December 23, 2010Date of Patent: July 1, 2014Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, III, Hitoshi Ban, Julia Gavrilyuk
-
Publication number: 20140178387Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: February 21, 2014Publication date: June 26, 2014Applicant: UCB Pharma S.A.Inventors: NEIL GOZZARD, ALASTAIR DAVID GRIFFITHS LAWSON, DANIEL JOHN LIGHTWOOD, ROGER THOMAS PALFRAMAN, BRYAN JOHN SMITH, KERRY LOUISE TYSON
-
Publication number: 20140178389Abstract: The disclosure provides binding proteins that specifically bind to IL-1? and IL-1?. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1? and/or IL-1? and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.Type: ApplicationFiled: July 12, 2013Publication date: June 26, 2014Applicant: ABBVIE, INC.Inventors: Susan E. LACY, Lorenzo BENATUIL, Meha CHHAYA, Emma FUNG, Renee MILLER, Ravi CHARI, Sarah J. HEIGHTON, Jacqueline G. BIXBY
-
Publication number: 20140178391Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: October 18, 2013Publication date: June 26, 2014Applicant: Celera CorporationInventors: Bruno DOMON, Aiqun LI, Tao HE, Ian MCCAFFREY
-
Patent number: 8758756Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.Type: GrantFiled: September 12, 2012Date of Patent: June 24, 2014Assignee: Industrial Technology Research InstituteInventors: Hsiang-Ching Wang, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
-
Publication number: 20140170677Abstract: The present invention relates to the use of a novel, isolated anti-CXCR4 antibody in the diagnosis of cancer. In particular, methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression, are disclosed.Type: ApplicationFiled: July 30, 2012Publication date: June 19, 2014Applicant: PIERRE FABRE MEDICAMENTInventors: Christine Klinguer-Hamour, Alexandra Jouhanneaud
-
Publication number: 20140170076Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 1, 2012Publication date: June 19, 2014Applicant: THE UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INCInventors: Paula J. Bates, Mohammad Tariq Malik, Kyung A. Kang
-
Publication number: 20140170148Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.Type: ApplicationFiled: April 20, 2012Publication date: June 19, 2014Applicant: GENMAB A/SInventors: Bart De Goeij, Patrick Van Berkel, Kristin Strumane, Aran Frank Labrijn, Joost J. Neijssen, Joyce I. Meesters, Paul Parren, Janine Schuurman
-
Publication number: 20140170681Abstract: The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer.Type: ApplicationFiled: July 30, 2012Publication date: June 19, 2014Inventors: Christine Klinguer-Hamour, Alexandra Jouhanneaud, Marie-Claire Janin-Bussat
-
Patent number: 8753829Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: GrantFiled: December 4, 2012Date of Patent: June 17, 2014Assignee: Alper Biotech, LLCInventor: Özge Alper
-
Patent number: 8753822Abstract: A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 6. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim 4, the software including analyzing means for analyzing the arrays.Type: GrantFiled: June 20, 2011Date of Patent: June 17, 2014Assignee: Wayne State UniversityInventors: Michael Tainsky, Sorin Draghici, Madhumita Chatterjee
-
Publication number: 20140161804Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: October 24, 2012Publication date: June 12, 2014Applicant: ABBVIE INC.Inventors: Carolyn Cuff, Jennifer Perez, Suju Zhong, Lucia Eaton, Anca Clabbers, Christine Grinnel, Edit Tarsca, Dora Forkas, Suzanne Mathieu
-
Publication number: 20140161814Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen.Type: ApplicationFiled: August 5, 2013Publication date: June 12, 2014Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventor: Nai-Kong V. CHEUNG
-
Publication number: 20140161870Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.Type: ApplicationFiled: July 15, 2013Publication date: June 12, 2014Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
-
Patent number: 8747856Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.Type: GrantFiled: May 4, 2010Date of Patent: June 10, 2014Assignee: Ribovax Biotechnologies S.A.Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson
-
Publication number: 20140154715Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.Type: ApplicationFiled: July 6, 2012Publication date: June 5, 2014Applicant: JANSSEN PHARMACEUTICA NVInventors: Marc Hubert Mercken, Marianne Borgers, Marc, Maria, Pierre, Pelagie Vandermeeren, Bianca Julia J Van Broeck
-
Publication number: 20140155583Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.Type: ApplicationFiled: December 13, 2013Publication date: June 5, 2014Applicant: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
-
Patent number: 8741289Abstract: Novel antibodies and antigen binding fragments that specifically binds to S?glec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of S?glec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of S?glec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: October 6, 2010Date of Patent: June 3, 2014Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Patent number: 8741615Abstract: A magnetic nanoparticle is provided in the disclosure. The magnetic nanoparticle includes a magnetic nanoparticle; a biocompatible polymer of the following formula (II) covalently coupled to the magnetic nanoparticle, wherein R1 is alkyl, aryl, carboxyl, or amino; n is an integer from 5 to 1000; and m is an integer from 1 to 10.Type: GrantFiled: August 30, 2012Date of Patent: June 3, 2014Assignee: Industrial Technology Research InstituteInventors: Wen-Hsiang Chang, Wen-Uan Hsieh, Shiu-Hua Huang, Chin-I Lin, Shian-Jy Jassy Wang, Kelly Teng
-
Patent number: 8734797Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8734801Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8735546Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: GrantFiled: August 2, 2011Date of Patent: May 27, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Publication number: 20140141002Abstract: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.Type: ApplicationFiled: November 8, 2013Publication date: May 22, 2014Applicant: The University of North Carolina at Chapel HillInventors: David R. Clemmons, Laura A. Maile
-
Publication number: 20140141992Abstract: A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immune-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.Type: ApplicationFiled: November 13, 2013Publication date: May 22, 2014Applicant: Wayne State UniversityInventors: Michael Tainsky, Sorin Draghici, Madhumita Chatterjee
-
Publication number: 20140140990Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: ApplicationFiled: March 28, 2012Publication date: May 22, 2014Applicants: National Research Council of Canada, Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Publication number: 20140141444Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
-
Publication number: 20140141445Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
-
Patent number: 8729258Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.Type: GrantFiled: April 30, 2012Date of Patent: May 20, 2014Assignee: The Regents of the University of CaliforniaInventors: Kenneth N. Raymond, Todd M. Corneillie, Jide Xu
-
Patent number: 8728740Abstract: Epitopes localized on FNIII-8 repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said epitope are also described.Type: GrantFiled: December 11, 2009Date of Patent: May 20, 2014Assignee: Sirius-Biotech S.R.L.Inventors: Patrizia Castellani, Francesca Sassi, M. Barbara Carnemolla, Laura Borsi, Enrica Balza
-
Publication number: 20140135484Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: November 22, 2013Publication date: May 15, 2014Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20140134179Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: ApplicationFiled: June 13, 2012Publication date: May 15, 2014Applicants: Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human ServicesInventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong
-
Publication number: 20140134703Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.Type: ApplicationFiled: July 19, 2013Publication date: May 15, 2014Applicant: Deutsches KrebsforschungszentrumInventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 8722855Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: October 28, 2010Date of Patent: May 13, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu